VISCHER AG advised Novaremed on the deal. Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through...
You must be a Standard 1 Year member to access this content.
VISCHER AG advises Polyphor AG on the deal. Walder Wyss advises Enbiotix Inc. on this transaction. Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late...
You must be a Standard 1 Year member to access this content.
SKYE PARTNERS, Weil, Gotshal & Manges, Clifford Chance, Pusch Wahlig Workplace Law, BCA-Law, DMZ Legal, herrmann legal, Disput Hübner and Vischer advised Invision. Baker McKenzie advised...
You must be a Standard 1 Year member to access this content.
VISCHER advised Combioxin SA on the deal. Combioxin SA, a clinical-stage biotechnology company based in Epalinges, Switzerland, entered into a worldwide licensing agreement with Eagle Pharmaceuticals,...
You must be a Standard 1 Year member to access this content.
VISCHER advised the sellers on this transaction. Wenger Vieli advised Atlas Antibodies. The shareholders of the evitria Group have sold the evitria Group to Atlas Antibodies,...
You must be a Standard 1 Year member to access this content.
VISCHER advised Swissphone on the deal. Rigeto portfolio company Swissphone acquired instaSOLUTION AG, which offers modern and efficient communication and management solutions in the areas of alerting,...
You must be a Standard 1 Year member to access this content.
Pestalozzi advised H.C. Wainwright LLC on the deal, while VISCHER advised Relief Therapeutics. RELIEF THERAPEUTICS Holding AG. a biopharmaceutical company seeking to provide patients therapeutic relief from...
You must be a Standard 1 Year member to access this content.
Vischer advised Meininger on the deal. International hotel group Meininger managed its successful market entry in Switzerland and opens new hotels in Zurich (174 rooms, 582 beds)...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest...
You must be a Standard 1 Year member to access this content.
VISCHER has advised TargImmune on the deal. TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m. TargImmune is a private Swiss-based biotechnology firm focused...
You must be a Standard 1 Year member to access this content.
VISCHER AG has advised Novartis AG in this transaction. Novartis has signed a collaboration agreement and an option to acquire Cellerys. The Zurich-based startup is researching...
You must be a Standard 1 Year member to access this content.
VISCHER acted as Swiss counsel to Dermavant in the transaction. Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, entered...
You must be a Standard 1 Year member to access this content.
